Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 151-160 of 525 results
Medicine, 2017 • July 1, 2017
The study aimed to evaluate the effects of hyperbaric oxygen (HBO) therapy on depression and anxiety in patients with incomplete spinal cord injury (ISCI). Sixty patients were divided into HBO, psycho...
KEY FINDING: HBO therapy and psychotherapy both significantly reduced depression (HAMD scores) compared to the control group.
Frontiers in Bioengineering and Biotechnology, 2023 • August 16, 2023
This review summarizes the progress of lipid nanovesicles for targeted treatment of SCI, discusses their advantages and challenges, and provides a perspective on their application. Most lipid nanovesi...
KEY FINDING: Lipid nanovesicles, including liposomes and extracellular vesicles, can be modified to enhance their ability to target specific cells and tissues in the spinal cord.
Comparative Medicine, 2018 • February 1, 2018
This study details a non-human primate model of traumatic spinal cord injury (TSCI) in cynomolgus macaques, induced using a balloon catheter in the epidural space, focusing on tail movement impairment...
KEY FINDING: The study found that the value of Q decreased on both the left and right side immediately after the lesion in both the treatment and control groups, suggesting that the lesion led to decreased EMG activity and decreased tail movement.
Clinics, 2018 • January 1, 2018
This study evaluated the effects of combined G-CSF and methylprednisolone treatment on rats with experimental spinal cord injury. The combination therapy resulted in superior functional and histologic...
KEY FINDING: The combination of methylprednisolone and G-CSF promoted greater functional improvement than methylprednisolone or G-CSF alone.
The Journal of Spinal Cord Medicine, 2019 • January 1, 2019
Current treatment of spinal cord injury (SCI) focuses on cord stabilization to prevent further injury, rehabilitation, management of non-motor symptoms, and prevention of complications. There is urgen...
KEY FINDING: There is urgent need to develop disease-modifying therapy for SCI, yet the commercial landscape remains small and highly fragmented with a paucity of novel late-stage compounds in R&D.
Toxins, 2018 • March 28, 2018
This retrospective observational study evaluated the efficacy and safety of IncobotulinumtoxinA in managing muscle spasticity, using doses from 100 to 1000 units, tailored to individual patient needs....
KEY FINDING: IncobotulinumtoxinA demonstrates a wide therapeutic window, allowing for safe and effective spasticity management with doses ranging from 100 to 1000 units, tailored to individual patient needs.
Toxins, 2018 • June 1, 2018
This review examines the mechanism of central neuropathic pain and assesses the effect of BTX on central neuropathic pain. The review summarizes the mechanism of central neuropathic pain and botulinum...
KEY FINDING: BTX inhibits the secretion of substance P and CGRP from dorsal root ganglion (DRG) neurons, reduces the expression of TRPV1 and P2X3 receptors, and induces a central effect through retrograde axonal transport, all of which contribute to its potential analgesic effects.
The Journal of Spinal Cord Medicine, 2019 • May 1, 2019
This retrospective study evaluated the effectiveness of botulinum toxin (BT) injections in treating spasticity in 90 patients with spinal cord injury (SCI). The results indicated that BT injections im...
KEY FINDING: Patients with focal spasticity experienced a significantly greater improvement in muscle tone compared to those with generalized spasticity.
Molecular Pain, 2018 • June 8, 2018
This study investigates the therapeutic potential of Pak1 inhibition for pain associated with cutaneous burn injury using romidepsin, an FDA-approved inhibitor. The findings demonstrate that Pak1 inhi...
KEY FINDING: Inhibition of Pak1 by romidepsin decreased dendritic spine dysgenesis in the dorsal horn of mice with burn injury.
Spinal Cord Series and Cases, 2018 • June 7, 2018
The author argues that cannabis is an effective pain reliever for individuals with spinal cord injuries and should be more accessible for both patients and researchers. The paper highlights the histor...
KEY FINDING: Patients with SCI and chronic pain report cannabis as the single most effective medication out of 26 pain treatments.